The global molecular breast imaging market was valued at USD 883.4 million in 2023 and is expected to reach USD 1.4 billion by 2033, reflecting a robust growth trajectory. With an estimated compound annual growth rate (CAGR) of 4.7% from 2023 to 2033, the market is poised to expand, supported by increasing demand for effective breast cancer diagnostic tools and innovations in imaging technology.
Molecular breast imaging, also known as breasts-specific gamma imaging (BSGI), is a specialized diagnostic technique that uses gamma cameras and radiopharmaceuticals to detect breast cancer. The modality provides a high sensitivity rate ranging from 89% to 96.4%, rivaling Magnetic Resonance Imaging (MRI) in accuracy. MBI is particularly effective in identifying high-risk lesions, such as atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), making it an important tool for diagnosing early-stage breast cancer, including invasive lobular carcinoma.
The screening application leads the global MBI market with an approximate 56.7% share in 2022, reflecting its dominant role in the adoption of MBI for breast cancer detection. While MBI is not recommended for routine screening, it plays a critical role in diagnostic evaluations, particularly for patients who cannot undergo MRI due to contraindications, women with dense breast tissue, and those with newly diagnosed breast cancer.
The increasing awareness of breast cancer prevalence, coupled with advancements in imaging techniques, is driving the growth of the MBI market. With its ability to detect tumors missed by traditional mammography, MBI offers patients a more reliable and accurate diagnostic option. The growing adoption of MBI technology in medical facilities worldwide, especially among women at higher risk or with dense breast tissue, is expected to continue fueling the market’s expansion.
The global MBI market is further bolstered by ongoing advancements in imaging technologies, improvements in radiopharmaceuticals, and increasing government and healthcare investments aimed at enhancing early breast cancer detection. As the medical industry evolves, MBI is expected to remain a key player in the early diagnosis and effective management of breast cancer.
Key Takeaways: Molecular Breast Imaging Market
- Market Size & Growth:
- The global molecular breast imaging market was valued at USD 846.7 million in 2022 and is projected to reach USD 1.4 billion by 2033, growing at a CAGR of 4.8% from 2023 to 2033.
- Regional Growth:
- United States: Expected to grow at a 4.5% CAGR from 2023 to 2033.
- Germany: Projected to experience a 5.8% CAGR over the same period.
- United Kingdom: Anticipated to grow at a 5.1% CAGR.
- Japan: Estimated to grow at a 5.0% CAGR.
- China: Expected to witness a 5.1% CAGR.
- India: Projected to grow at a 4.9% CAGR.
- Market Share by Modality:
- The dual-head camera modality dominated the market with 61.4% of the global market share in 2022.
- Application Segment:
- Screening applications accounted for a substantial 56.7% of the molecular breast imaging market, valued at USD 480.1 million in 2022.
- End-User Breakdown:
- Hospitals remain the dominant end-user, representing 41.4% of the market share in 2022.
Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!
Competitive Landscape:
Innovation and strategic acquisitions within healthcare providers, research institutions, and technology companies are driving the advancement of molecular breast imaging. Collaborative efforts in research, development, and commercialization are expanding market reach and fostering new applications. The market is highly competitive, with several major players actively involved in the field.
Notable developments include:
- In March 2023, Philips launched the Zenition 10 image-guided therapy system, a cost-effective, high-quality solution leveraging flat panel detector technology to enhance patient outcomes in surgical care, trauma, and orthopaedics.
- In July 2021, Fujifilm Healthcare Europe acquired Hitachi Diagnostic Imaging for 179 billion yen, broadening its portfolio of clinical solutions across CT, MRI, ultrasound, x-ray, women’s health, AI, PACS, and IVD.
Key Companies Profiled:
- Koninklijke Philips N.V. (Netherlands)
- Hitachi Ltd. (Japan)
- Siemens Healthcare GmbH (Germany)
- CANON MEDICAL SYSTEMS CORPORATION (Japan)
- General Electric (US)
- Aspect Imaging Ltd (Israel)
- Bruker (US),
- Aurora Health Care (US)
- FONAR Corp. (US)
- ESAOTE SPA (Italy)
- Neusoft Corporation (China)
- TOSHIBA CORPORATION (Japan)
- Sanrad Medical Systems Private Limited (India)
- FUJIFILM Holdings Corporation (Japan)
Key Market Segments Covered in the Molecular Breast Imaging Industry Research:
By Modality:
- Single Head Gamma Camera
- Dual Head Camera
By Application:
- Screening
- Diagnosis
By End User:
- Hospital
- Diagnostic Imaging Centers
- Breast Cancer Care
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
